Nonhospitalized, high-risk, vaccinated COVID-19 patients who received nirmatrelvir-ritonavir (NMV-r, or Paxlovid) saw a 45% drop in their relative risk of emergency department (ED) visits, hospitalization, and death by 30 days, suggests a study published late last week in Clinical Infectious Diseases.
A new study offers a complex picture of COVID-19 incidence among the US homeless population and illustrates the difficulty of tracking disease spread among this population. The study was published today in JAMA Network Open and found the incidence of the disease lower than among the general population.
The risk of myocarditis and/or pericarditis was not significantly different among children ages 5 to 11 years after COVID-19 vaccination from that of unvaccinated children and much lower than that among children aged 12 to 17, finds a prospective study in Denmark published today in Pediatrics.
UK researchers found E coli with resistance to third-generation cephalosporins in 8% of fecal samples.
A report yesterday from the United Kingdom's Food Standards Agency (FSA) shows that that the prevalence of antibiotic-resistant Escherichia coli in retail beef and pork samples remains low.
An increase in resistance to ciprofloxacin among poultry isolates was primarily due to Salmonella Infantis.
Three new studies to be presented at the upcoming European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) conference at the end of the month demonstrate benefits of the antiviral molnupiravir against COVID-19 infections, including evidence that Merck's pill reduces symptoms of the SARS-CoV-2 virus by day 3 of administration.
The Indiana Board of Animal Health (IBAH) said today that initial tests at a third turkey farm in the state are positive for H5 avian flu. The new detection marks the United States' fifth recent outbreak in poultry. Further testing is under way to assess if the virus is the same highly pathogenic H5N1 strain that struck the first Indiana farm.
A 3-year prospective audit and feedback (PAF) intervention led by pharmacists at a Japanese hospital was linked to reduced antibiotic duration and more appropriate antibiotic use in patients with Escherichia coli bacteremia, Japanese researchers reported yesterday in the American Journal of Infection Control.
Danish microbiome technology company SNIPR Biome ApS announced this week that the US Food and Drug Administration has approved the company's application to initiate the first human clinical trial of its CRISPR-based drug for preventing Escherichia coli infections in cancer patients.
